The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Shionogi Pharma, 5 Other Firms to Form Continuous Manufacturing JV
A group of six companies including Shionogi Pharma said on November 24 that they will set up a joint venture by the end of this month for developing continuous manufacturing technologies for APIs and intermediates and offering CDMO services based…
To read the full story
Related Article
- Pharmira Looks to Offer One-Stop API/Intermediate CDMO Services, Expand with Continuous Manufacturing Tech
May 27, 2022
- Shionogi-Led Continuous Manufacturing JV Now Up and Running
April 4, 2022
- Shionogi Pharma Eyes 10 Billion Yen Sales in CDMO Business in FY2022
December 17, 2021
- Shionogi, Chiyoda Eye JV for Continuous Manufacturing of APIs, Intermediates
June 2, 2021
BUSINESS
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
- Shionogi, Salubritas Tie Up on Hair Cell Regeneration R&D for Hearing Loss
December 24, 2025
- Guardant360 Approved in Japan as CDx for Lilly’s Inluriyo
December 24, 2025
- Meiji Pharma Sets Up Singapore Unit to Bolster ASEAN Push
December 24, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…